Henry20feb_
$AYTU AYTU’s FY26 numbers look weak on the surface, but Q4 tells a very different story. Revenue rebounded to $16.1M, EXXUA jumped from $2.4M to $3.9M QoQ with prescriptions up 138%, and adjusted EBITDA returned positive at $0.5M, while cash remains solid at $26.3M. The legacy ADHD business is still declining YoY, but if EXXUA continues anywhere near its current trajectory, its first full commercial year could clearly outperform the ~$10M probability-weighted forecast — Q4 may well mark the turning point.
4
